Scientific Research News

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced financial results for the quarter ended June 30, 2026, and provided an operational update. “We delivered a second quarter marked by year-over-year and strong sequential growth. We continued strengthening our f...

DUBLIN--(BUSINESS WIRE)--Prothena reported financial results for the second quarter and first six months of 2026 and provided business highlights....

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today reported financial results for the three and six months ended June 30, 2026, provided operating and partner program progress, and updated 2026 financial guidance. “We are pleased to report a strong quarter and to increase our revenue and cash outlook for 2026 based on continued momentum in our business. Recent u...

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the second quarter ended June 30, 2026, and provided a business update. "There are still no first-line oral options for patients suffering with AD that combine lesion control, itch relief and tolerability. That gap is where we...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced business updates and financial results for the second quarter ended June 30, 2026. Recent Business Highlights Cash and cash equivalents totaled $101.6 million as of June 30, 2026. During Q2 the Company raised $46.8 million in net proceeds through an at-the-market (ATM) program, raising approxim...

CARLSBAD, Calif.--(BUSINESS WIRE)--Q2 2026 Earnings Release...

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the second quarter ended June 30, 2026, together with other business updates. Key Financial Results: Quarterly revenue of $51.4 million, Net loss of $(21.6) million, and Adjusted EBITDA of $8.7 million; Full year 2026 Adjusted EBITDA guidance raised to $33 million to $35 milli...

SAN CARLOS, Calif.--(BUSINESS WIRE)--Cerepeut, Inc., a biotechnology company developing mitochondrial therapeutics for neurodegenerative disease, today announced publication of a landmark study in Neuron revealing why the brain turns on itself in Alzheimer's disease and related disorders, and unveiling a drug candidate designed to stop it. Tau is a well-known driver of Alzheimer's, notorious for clumping into toxic tangles inside dying neurons. What scientists didn't know was that tau also moon...

COLUMBUS, Ohio--(BUSINESS WIRE)--Battelle recently welcomed members of the National Security Commission on Emerging Biotechnology (NSCEB) to its Columbus headquarters as part of the NSCEB’s national roadshow providing an inside look at biotechnology research, biosecurity capabilities and partnerships advancing U.S. competitiveness, supply chain resilience and national security. The visit brought together Commission members, congressional staff, biotechnology leaders, government partners, academ...

--(BUSINESS WIRE)--General Atomics: WHAT: San Diego will once again have a rare opportunity to step inside one of the nation’s leading fusion research facilities. After drawing strong public interest in the spring, General Atomics is reopening the DIII-D National Fusion Facility for public tours this October in celebration of Nuclear Science Week. DIII-D (pronounced “Dee-three-dee”) is a U.S. Department of Energy Office of Science user facility operated by General Atomics and the largest operat...